$FENC
FENNEC PHARMACEUTICALS INC.

2014 Q4 Form 10-Q Financial Statement

#000114420414067837 Filed on November 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2014 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $630.0K $530.0K $860.0K
YoY Change 90.91% 89.29% 132.43%
% of Gross Profit
Research & Development $170.0K $88.00K $72.00K
YoY Change 88.89% -139.29% -87.0%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $790.0K $88.00K $72.00K
YoY Change 88.1% 72.55% -92.23%
Operating Profit -$619.0K -$930.0K
YoY Change 1113.73% 0.32%
Interest Expense $2.180M $0.00 $0.00
YoY Change 42.48%
% of Operating Profit
Other Income/Expense, Net $999.0K $180.0K
YoY Change -158.25% -97.61%
Pretax Income $1.390M $380.0K -$750.0K
YoY Change 25.23% -121.47% -111.35%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $1.390M $380.0K -$750.0K
YoY Change 25.23% -121.52% -111.35%
Net Earnings / Revenue
Basic Earnings Per Share $0.04 -$0.08
Diluted Earnings Per Share $140.4K $0.03 -$0.08
COMMON SHARES
Basic Shares Outstanding 9.861M shares 9.861M shares 9.846M shares
Diluted Shares Outstanding 11.15M shares 9.846M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.310M $590.0K $1.020M
YoY Change 39.16% 9.26% 0.99%
Cash & Equivalents $2.307M $593.0K $1.015M
Short-Term Investments
Other Short-Term Assets $17.00K $13.00K $40.00K
YoY Change 112.5% 1200.0% 1233.33%
Inventory
Prepaid Expenses $48.00K $67.00K
Receivables
Other Receivables
Total Short-Term Assets $2.370M $670.0K $1.050M
YoY Change 35.43% 4.69% 1.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.000K $3.000K $0.00
YoY Change 0.0%
TOTAL ASSETS
Total Short-Term Assets $2.370M $670.0K $1.050M
Total Long-Term Assets $2.000K $3.000K $0.00
Total Assets $2.372M $673.0K $1.050M
YoY Change 35.39% 5.16% 1.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $308.0K $364.0K $340.0K
YoY Change 45.28% 15.56% -52.51%
Accrued Expenses $132.0K $38.00K $40.00K
YoY Change 0.0% -41.54% -38.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.759M $3.901M $5.710M
YoY Change -45.15% -18.22% 65.03%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.759M $3.901M $5.710M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.759M $3.901M $5.710M
YoY Change -45.15% -18.17% 65.08%
SHAREHOLDERS EQUITY
Retained Earnings -$110.9M
YoY Change 2.0%
Common Stock $110.2M $107.8M
YoY Change 4.0% 3.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $613.0K -$3.228M -$4.658M
YoY Change
Total Liabilities & Shareholders Equity $2.372M $673.0K $1.050M
YoY Change 35.39% 5.16% 1.94%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2014 Q2
OPERATING ACTIVITIES
Net Income $1.390M $380.0K -$750.0K
YoY Change 25.23% -121.52% -111.35%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change
Cash From Operating Activities -$470.0K -$443.0K -$410.0K
YoY Change 6.82% -5.54% -53.88%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $21.00K $87.00K
YoY Change
Debt Paid & Issued, Net $0.00 $0.00
YoY Change
Cash From Financing Activities 2.180M $21.00K $87.00K
YoY Change 38.85%
NET CHANGE
Cash From Operating Activities -470.0K -$443.0K -$410.0K
Cash From Investing Activities 0.000 $0.00 $0.00
Cash From Financing Activities 2.180M $21.00K $87.00K
Net Change In Cash 1.710M -$422.0K -$323.0K
YoY Change 51.33% -10.02% -63.67%
FREE CASH FLOW
Cash From Operating Activities -$470.0K -$443.0K -$410.0K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$443.0K -$410.0K
YoY Change -5.54% -53.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 us-gaap Assets
Assets
673000 USD
CY2014Q3 us-gaap Liabilities
Liabilities
3901000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
3207000 USD
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
81000 USD
CY2014Q3 us-gaap Other Assets Current
OtherAssetsCurrent
13000 USD
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
364000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
212000 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3901000 USD
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
38000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1663000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3207000 USD
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8000 USD
CY2014Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
67000 USD
CY2014Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3499000 USD
CY2013Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2863000 USD
CY2013Q4 us-gaap Assets
Assets
1752000 USD
CY2014Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
180 shares
CY2014Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.50
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
593000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
132000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-1455000 USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
us-gaap Net Income Loss
NetIncomeLoss
-3564000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-1766000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
380000 USD
CY2013Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
108698000 USD
CY2013Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
1635000 USD
CY2013Q4 us-gaap Cash
Cash
39000 CAD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
2254000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
66790000 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
39210000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1752000 USD
CY2014Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
189000 USD
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0213 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0215 pure
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.4 pure
CY2014Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
593000 USD
CY2014Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2013Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9861 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9719 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9861 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9719 shares
CY2014Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
499000 USD
CY2014Q3 us-gaap Cash
Cash
94000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
9000 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Use of estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>&#160;</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period.&#160;Significant estimates include certain accruals, valuation of derivative warrant liability and the value of stock based compensation.&#160;Actual results could differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In the opinion of management, these unaudited interim consolidated financial statements include all normal and recurring adjustments, considered necessary for the fair presentation of the Company&#8217;s financial position at September 30, 2014, and to state fairly the results for the periods presented. The most significant estimates included in these financial statements are the derivative instruments described in Note 3. There were significant changes in their valuation during the quarter ended, and for the nine-month period ended September 30, 2014.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
66790000 USD
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41001000 USD
CY2014Q3 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
112262000 USD
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
-3228000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
673000 USD
CY2014Q3 us-gaap Cash
Cash
24000 CAD
CY2013Q4 us-gaap Cash
Cash
28000 USD
CY2013Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1708000 USD
CY2014Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.44
CY2014Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3835000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
544000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
503000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
110000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
923000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.60
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.11
us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.01
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
31.84
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.66
CY2014Q3 us-gaap Deferred Compensation Arrangement With Individual Shares Authorized For Issuance
DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance
133332000 shares
CY2014Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
4.32
CY2010Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2465000 shares
adhxf Percentage Of Common Shares Outstanding
PercentageOfCommonSharesOutstanding
0.0093 pure
CY2010Q2 adhxf Percentage Of Common Shares Outstanding
PercentageOfCommonSharesOutstanding
0.25 pure
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
97000 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
790000 USD
CY2013Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
68000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.63 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.0227 pure
CY2014Q3 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
3499000 USD
CY2014Q3 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
4092000 USD
CY2013Q1 adhxf Issue Of Convertible Common Stock As Per Licence Agreement
IssueOfConvertibleCommonStockAsPerLicenceAgreement
4634000 shares
CY2013Q1 adhxf Expired Convertible Common Stock
ExpiredConvertibleCommonStock
7083000 shares
CY2013Q1 adhxf Milestone Payment Fees
MilestonePaymentFees
100000 USD
CY2013Q3 us-gaap Revenues
Revenues
0 USD
CY2014Q3 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
507000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
192000 USD
CY2013Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
-224000 USD
CY2014Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
88000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
69957000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2013Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2014Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
386000 USD
adhxf Gain On Deferred Lease Inducements
GainOnDeferredLeaseInducements
0 USD
adhxf Gain On Deferred Lease Inducements
GainOnDeferredLeaseInducements
0 USD
CY2013Q3 adhxf Gain On Deferred Lease Inducements
GainOnDeferredLeaseInducements
0 USD
CY2014Q3 adhxf Gain On Deferred Lease Inducements
GainOnDeferredLeaseInducements
0 USD
adhxf Gain On Deferred Lease Inducements
GainOnDeferredLeaseInducements
497000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2013Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2014Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
13094000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1008000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1894000 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
275000 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
531000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35322000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1515000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2086000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-51000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-619000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-118262000 USD
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2013Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
CY2014Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 USD
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-1283000 USD
CY2014Q3 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
619000 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
5179000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
-8000 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
0 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
0 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
19000 USD
us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-1855000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
-3000 USD
CY2013Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
-7000 USD
CY2014Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2900000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2249000 USD
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
253000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
3000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
1000 USD
CY2013Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
0 USD
CY2014Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
0 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1478000 USD
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1715000 USD
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
999000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7409000 USD
us-gaap Net Income Loss
NetIncomeLoss
734000 USD
us-gaap Net Income Loss
NetIncomeLoss
-110853000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.09
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8386000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9861000 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8386000 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9861000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8549000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9861000 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8386000 shares
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11154000 shares
us-gaap Net Income Loss
NetIncomeLoss
-110853000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
2254000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-1855000 USD
CY2013Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-1708000 USD
CY2014Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
619000 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
5179000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 USD
CY2013Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 USD
CY2014Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1404000 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
CY2013Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
CY2014Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
1187000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 USD
CY2013Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 USD
CY2014Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-36000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
386000 USD
adhxf Amortization Of Tenant Inducements Received
AmortizationOfTenantInducementsReceived
0 USD
adhxf Amortization Of Tenant Inducements Received
AmortizationOfTenantInducementsReceived
0 USD
CY2013Q3 adhxf Amortization Of Tenant Inducements Received
AmortizationOfTenantInducementsReceived
0 USD
CY2014Q3 adhxf Amortization Of Tenant Inducements Received
AmortizationOfTenantInducementsReceived
0 USD
adhxf Amortization Of Tenant Inducements Received
AmortizationOfTenantInducementsReceived
412000 USD
us-gaap Severance Costs1
SeveranceCosts1
0 USD
us-gaap Severance Costs1
SeveranceCosts1
0 USD
CY2013Q3 us-gaap Severance Costs1
SeveranceCosts1
0 USD
CY2014Q3 us-gaap Severance Costs1
SeveranceCosts1
0 USD
us-gaap Severance Costs1
SeveranceCosts1
168000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
251000 USD
CY2013Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
27000 USD
CY2014Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
122000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1324000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
97000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
539000 USD
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
41000 USD
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
67000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
10870000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
13094000 USD
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
342000 USD
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
-67000 USD
CY2013Q3 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
479000 USD
CY2014Q3 us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
14000 USD
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
124000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1765000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1231000 USD
CY2013Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-469000 USD
CY2014Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-443000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-88478000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2013Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2014Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1440000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2013Q3 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
CY2014Q3 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
115000 USD
us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
0 USD
us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
0 USD
CY2013Q3 us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
0 USD
CY2014Q3 us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
0 USD
us-gaap Proceeds From Sale Of Other Productive Assets
ProceedsFromSaleOfOtherProductiveAssets
24000 USD
us-gaap Decrease In Restricted Cash
DecreaseInRestrictedCash
0 USD
us-gaap Decrease In Restricted Cash
DecreaseInRestrictedCash
0 USD
CY2013Q3 us-gaap Decrease In Restricted Cash
DecreaseInRestrictedCash
0 USD
CY2014Q3 us-gaap Decrease In Restricted Cash
DecreaseInRestrictedCash
0 USD
us-gaap Decrease In Restricted Cash
DecreaseInRestrictedCash
190000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
CY2013Q3 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
CY2014Q3 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
209000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
CY2013Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
CY2014Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
22148000 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 USD
CY2013Q3 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 USD
CY2014Q3 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0 USD
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
22791000 USD
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0 USD
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0 USD
CY2013Q3 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0 USD
CY2014Q3 us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0 USD
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
166000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2013Q3 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
CY2014Q3 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
640000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2013Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2014Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1483000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
CY2013Q3 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
CY2014Q3 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
0 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
68000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2013Q3 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2014Q3 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
65000 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
0 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
0 USD
CY2013Q3 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
0 USD
CY2014Q3 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
0 USD
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
8000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161000 USD
CY2013Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2014Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
88174000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2013Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2014Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
465000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2013Q3 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2014Q3 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
544000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2013Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2014Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3017000 USD
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
0 USD
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
0 USD
CY2013Q3 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
0 USD
CY2014Q3 us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
0 USD
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
87000 USD
us-gaap Proceeds From Other Deposits
ProceedsFromOtherDeposits
0 USD
us-gaap Proceeds From Other Deposits
ProceedsFromOtherDeposits
0 USD
CY2013Q3 us-gaap Proceeds From Other Deposits
ProceedsFromOtherDeposits
0 USD
CY2014Q3 us-gaap Proceeds From Other Deposits
ProceedsFromOtherDeposits
0 USD
us-gaap Proceeds From Other Deposits
ProceedsFromOtherDeposits
35000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2013Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
CY2014Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
161000 USD
CY2013Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2014Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
90176000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2013Q3 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2014Q3 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
378000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1765000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1070000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-469000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-422000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
593000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2303000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1007000 USD
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1015000 USD
CY1996Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
538000 USD
CY1996Q3 us-gaap Stockholders Equity
StockholdersEquity
0 USD
CY2004 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
18000 USD
CY2005 us-gaap Stockholders Equity Other
StockholdersEquityOther
-141000 USD
CY2007 adhxf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
694000 USD
CY2014Q2 adhxf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
0 USD
CY2014Q3 adhxf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
21000 USD
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
493000 USD
CY2003 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
1058000 USD
CY2004 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
1983000 USD
CY1999 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1615000 USD
CY2000 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
793000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
0 USD
CY2005 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25000 USD
CY2014Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
53000 USD
CY2014Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
87000 USD
CY2003 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000 USD
CY2004 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
23000 USD
CY2000 adhxf Equity Rights Offering
EquityRightsOffering
171000 USD
CY2004 adhxf Stock Issued During Period Value Merger
StockIssuedDuringPeriodValueMerger
-22000 USD
CY2003 us-gaap Dividends Cash
DividendsCash
158000 USD
CY2003 adhxf Stated Capital Adjustment
StatedCapitalAdjustment
0 USD
CY1999 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
20000 USD
CY2001 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
182000 USD
CY2002 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11000 USD
CY2003 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-159000 USD
CY2004 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-219000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1392000 USD
CY2005 us-gaap Net Income Loss
NetIncomeLoss
-13871000 USD
CY2006 us-gaap Net Income Loss
NetIncomeLoss
-16440000 USD
CY2007 us-gaap Net Income Loss
NetIncomeLoss
-13357000 USD
CY2008 us-gaap Net Income Loss
NetIncomeLoss
-13600000 USD
CY2009 us-gaap Net Income Loss
NetIncomeLoss
-3012000 USD
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-7824000 USD
CY2011 us-gaap Net Income Loss
NetIncomeLoss
4685000 USD
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-5163000 USD
CY2013 us-gaap Net Income Loss
NetIncomeLoss
1845000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-3194000 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-750000 USD
CY1998 us-gaap Net Income Loss
NetIncomeLoss
-398000 USD
CY1999 us-gaap Net Income Loss
NetIncomeLoss
-958000 USD
CY2000 us-gaap Net Income Loss
NetIncomeLoss
-1605000 USD
CY2001 us-gaap Net Income Loss
NetIncomeLoss
-2524000 USD
CY2002 us-gaap Net Income Loss
NetIncomeLoss
-3732000 USD
CY2003 us-gaap Net Income Loss
NetIncomeLoss
-17795000 USD
CY2004 us-gaap Net Income Loss
NetIncomeLoss
-6872000 USD
us-gaap Net Income Loss
NetIncomeLoss
-6594000 USD
us-gaap Net Income Loss
NetIncomeLoss
-37000 USD
CY2005Q4 us-gaap Stockholders Equity
StockholdersEquity
11077000 USD
CY2006Q4 us-gaap Stockholders Equity
StockholdersEquity
1268000 USD
CY2007Q4 us-gaap Stockholders Equity
StockholdersEquity
14148000 USD
CY2008Q4 us-gaap Stockholders Equity
StockholdersEquity
3053000 USD
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
406000 USD
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
-4926000 USD
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-120000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-4957000 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
-4334000 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
-4658000 USD
CY1998Q2 us-gaap Stockholders Equity
StockholdersEquity
-435000 USD
CY1999Q2 us-gaap Stockholders Equity
StockholdersEquity
242000 USD
CY2000Q2 us-gaap Stockholders Equity
StockholdersEquity
47000 USD
CY2001Q2 us-gaap Stockholders Equity
StockholdersEquity
9792000 USD
CY2002Q2 us-gaap Stockholders Equity
StockholdersEquity
6071000 USD
CY2003Q2 us-gaap Stockholders Equity
StockholdersEquity
698000 USD
CY2004Q2 us-gaap Stockholders Equity
StockholdersEquity
20454000 USD
CY2004Q4 us-gaap Stockholders Equity
StockholdersEquity
16654000 USD
CY1997Q2 us-gaap Stockholders Equity
StockholdersEquity
-37000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
FENNEC PHARMACEUTICALS INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001211583
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
ADHXF
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9860517 shares
us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
0 USD
us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-379000 USD
CY2013Q3 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
0 USD
CY2014Q3 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-379000 USD
us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-379000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
-5000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.89
adhxf Unrealized Gain On Derivatives Settlements
UnrealizedGainOnDerivativesSettlements
0 USD
adhxf Unrealized Gain On Derivatives Settlements
UnrealizedGainOnDerivativesSettlements
379000 USD
CY2013Q3 adhxf Unrealized Gain On Derivatives Settlements
UnrealizedGainOnDerivativesSettlements
0 USD
CY2014Q3 adhxf Unrealized Gain On Derivatives Settlements
UnrealizedGainOnDerivativesSettlements
379000 USD
adhxf Unrealized Gain On Derivatives Settlements
UnrealizedGainOnDerivativesSettlements
379000 USD
CY2014Q3 adhxf Exchange Of Warrants
ExchangeOfWarrants
840000 USD
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03

Files In Submission

Name View Source Status
0001144204-14-067837-index-headers.html Edgar Link pending
0001144204-14-067837-index.html Edgar Link pending
0001144204-14-067837.txt Edgar Link pending
0001144204-14-067837-xbrl.zip Edgar Link pending
adhxf-20140930.xml Edgar Link completed
adhxf-20140930.xsd Edgar Link pending
adhxf-20140930_cal.xml Edgar Link unprocessable
adhxf-20140930_def.xml Edgar Link unprocessable
adhxf-20140930_lab.xml Edgar Link unprocessable
adhxf-20140930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v392878_10q.htm Edgar Link pending
v392878_ex31-1.htm Edgar Link pending
v392878_ex31-2.htm Edgar Link pending
v392878_ex32-1.htm Edgar Link pending